GPHN and Dravet syndrome: Quantitative FDT analyses were used to assess postsynaptic levels of the excitatory marker PSD-95 and inhibitory marker GPHN in PCx from individuals with AD dementia or DS with ADNC, and from non-demented controls (Fig. 1; see Table 1 and Supplementary Data 1 for summarized and detailed demographic information).